B. Riley Analysts Reduce Earnings Estimates for Perspective Therapeutics, Inc. (NYSE:CATX)

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities research analysts at B. Riley lowered their Q2 2024 EPS estimates for Perspective Therapeutics in a research note issued to investors on Monday, July 1st. B. Riley analyst Y. Zhi now forecasts that the company will post earnings per share of ($0.21) for the quarter, down from their previous forecast of ($0.20). B. Riley has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.01) per share. B. Riley also issued estimates for Perspective Therapeutics’ Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.85) EPS and FY2025 earnings at ($1.01) EPS.

Other analysts have also recently issued research reports about the stock. Lifesci Capital reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of Perspective Therapeutics in a research note on Friday, June 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $19.00.

Perspective Therapeutics Trading Up 2.4 %

Shares of CATX opened at $10.74 on Wednesday. Perspective Therapeutics has a one year low of $2.05 and a one year high of $19.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.33 million for the quarter.

Insider Activity

In related news, CEO Johan M. Spoor acquired 10,000 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were purchased at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the completion of the acquisition, the chief executive officer now owns 13,757 shares of the company’s stock, valued at $160,956.90. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In other Perspective Therapeutics news, CFO Jonathan Robert Hunt bought 2,500 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were bought at an average price of $14.00 per share, for a total transaction of $35,000.00. Following the acquisition, the chief financial officer now directly owns 34,171 shares of the company’s stock, valued at approximately $478,394. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Johan M. Spoor bought 10,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was acquired at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the acquisition, the chief executive officer now directly owns 13,757 shares in the company, valued at $160,956.90. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 30,814 shares of company stock worth $385,487. Company insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. ZWJ Investment Counsel Inc. bought a new stake in Perspective Therapeutics in the 1st quarter worth about $26,000. Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at approximately $40,000. Bleakley Financial Group LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at approximately $40,000. RIA Advisory Group LLC grew its position in shares of Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after acquiring an additional 99,293 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at approximately $138,000. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.